PubMed Health⌕ Search

Biomedical subjects

A Dhala

Publications and source records attributed to A Dhala.

At least 55 records · Page 3Linked to original sources
PubMed1996

Sudden death in patients with implantable cardioverter-defibrillators.

UNLABELLED: Of the 733 patients with implantable cardioverter-defibrillators (ICDs) from 1982 to 1995 in our center, 20 died suddenly while the ICD was activated. This number included 16 men and four women with a mean age of 60 +/- 8 years and ejection fractions of 24.2% +/- 8.6%. ICDs were implanted for drug refractory ventricular tachycardia (VT) in 13 patients and for resucitated cardiac arrest in seven patients. The clinical VT was associated with syncope in 7 of 13 patients. VT was induced in 18 patients and was hemodynamically unstable in 12 patients. Shock therapies associated with syncope were delivered in 7 of 15 patients during the follow-up. This subgroup of patients survived a median of only 18 months after ICD implant. Ventricular fibrillation-defibrillation was found to surround death in nine patients. CONCLUSIONS: (1) Sudden death victims of the ICD population are characterized by poor left ventricular function and hemodynamically unstable ventricular tachyarrhythmias. (2) Ventricular tachyarrhythmias are the major cause of sudden death in ICD patients.

Aged↗
PubMed1996

Verapamil sensitive incessant ventricular tachycardia in the newborn.

Incessant VTs in infancy are often poorly tolerated. Response to conventional antiarrhythmic therapy is disappointing. The present case involves a 3-week-old infant with an incessant VT of a left bundle branch block, and normal axis morphology. This tachycardia was inducible with both atrial and ventricular pacing, but not by premature stimulation. Tachycardia persisted despite treatment with adenosine, esmolol, procainamide, and flecainide. Intravenous verapamil suppressed tachycardia and prevented inducibility, and no further recurrences were seen on oral verapamil. This case suggests that some incessant VTs in infancy may be due to calcium channel related afterdepolarizations or triggered activation.

Anti-Arrhythmia Agents↗
PubMed1996

Relative efficacy of different tilts with biphasic defibrillation in humans.

OBJECTIVE: The goal of this study was to assess if tilt bears any impact on defibrillation efficacy of biphasic shocks. BACKGROUND: Although it has been shown that biphasic waveform may increase the defibrillation efficacy, this pulsing method has not been as extensively studied in patients, and information regarding the effect of different tilts is lacking. METHODS: This study consisted of two similar but distinct protocols including 33 patients undergoing transvenous defibrillator implant. In 17 patients (Part I) defibrillation threshold was obtained delivering biphasic waveforms with 50%, 65%, and 80% tilt in random fashion. Similarly, in 16 patients (Part II) testing of biphasic waveform with 40%, 50%, and 65% tilt was performed in random order. The electrode system used consisted of two transvenous leads and a subcutaneous patch in all 33 patients. RESULTS: In Part I, tilt of 50% demonstrated a defibrillation threshold significantly lower than 65% tilt (7.5 +/- 4.3 J vs 9.7 +/- 5.0 J; P = 0.04) and 80% tilt (7.5 +/- 4.3 J vs 11.7 +/- 5.9 J; P < 0.01). Similarly, 65% tilt provided a lower defibrillation threshold than 80% tilt (9.7 +/- 5.0 J vs 11.7 +/- 5.9 J; P = 0.02). In Part II, no significant difference was observed in terms of defibrillation threshold between 40% tilt and the two tilts of 50% and 65%. However, as in Part I, 50% tilt provided a significant reduction of the energy to defibrillate as compared to 65% tilt (6.3 +/- 3.6 J vs 9.0 +/- 4.8 J; P < 0.01). The 50% tilt resulted in better defibrillation efficacy than 65% tilt independent of the lead system used for testing (Medtronic Transvene and CPI Endotak-C). CONCLUSIONS: Biphasic shocks with 50% tilt required less energy for defibrillation than 40%, 65%, and 80% tilts. However, in the clinical setting a programmable tilt may be preferable to account for some patient-to-patient variability.

Adult↗
PubMed1996

Response to beta blockers in patients with neurocardiogenic syncope: how to predict beneficial effects.

UNLABELLED: No definitive data are available about the possibility of predicting improvement in patients with neurocardiogenic syncope treated with beta blockers. Among 112 patients with syncope and a positive head-up tilt test (HUT), independent predictors for prevention of symptoms with beta blockers were determined using the Cox proportional hazards model. Each patient underwent HUT at 70 degrees for 20 minutes both in the drug-free state and during isoproterenol infusion given to increase the heart rate by at least 25%. Fifty-nine patients had a positive HUT during isoproterenol infusion and 53 in the drug-free state. All patients were then given esmolol infusion at 500 micrograms/kg per minute for 3 minutes followed by 300 micrograms/kg per minute maintenance dose. HUT was then repeated as previously described with or without isoproterenol, depending upon the initial positive response. Regardless of the response during esmolol, all patients were treated with metoprolol 50 to 100 mg twice daily. At follow-up, 36 patients experienced symptom relapse. Four of them had negative HUT on esmolol, whereas the remaining 32 did not respond to the acute infusion of esmolol. Only four patients with positive HUT on esmolol had a favorable response to metoprolol. Patients responding to metoprolol were older (55 +/- 12 years vs 42 +/- 15 years, P < 0.05). Response to metoprolol was predicted by a negative test on esmolol (P < 0.0001) and a positive HUT on isoproterenol (P < 0.001). Age older than 42 years was also associated with a higher likelihood of metoprolol success (P < 0.02). CONCLUSION: Acute challenge with esmolol infusion appears to be an accurate predictor of response to chronic beta blockers, together with age and a positive HUT during low-dose isoproterenol infusion.

Adrenergic beta-Agonists↗
PubMed1995

Provocation of hypotension during head-up tilt testing in subjects with no history of syncope or presyncope.

BACKGROUND: Head-up tilt test is increasingly being used to evaluate patients with syncope. This study was designed to evaluate the specificity of head-up tilt testing using different tilt angles and isoproterenol infusion doses in normal volunteers with no prior history of syncope or presyncope. METHODS AND RESULTS: One hundred fifty volunteers were randomized to two groups of 75 each. In group 1, subjects were further randomized to have head-up tilt testing at a 60, 70, or 80 degree angle at baseline followed by repeat tilt testing during a low-dose isoproterenol infusion that increased the heart rate by an average of 20%. In group 2, after having a baseline head-up tilt test at a 70 degree angle for a maximum of 20 minutes, subjects were randomized to have a repeat tilt table testing at a 70 degree angle during a low-dose, 3 micrograms/min, or 5 micrograms/min isoproterenol infusion. In group 1, syncope or presyncope along with hypotension developed in 2 subjects during the baseline test at 60 and 70 degrees of tilt and in 5 subjects during tilting at 80 degrees. The addition of low-dose isoproterenol reduced the specificity minimally from 92% to 88% at both 60 and 70 degrees of tilt but substantially to 60% at an 80 degrees angle. However, 6 of the 10 subjects with a positive test at an 80 degree angle had an abnormal response after 10 minutes of tilt testing. In group 2, using various isoproterenol doses with tilt table testing at a 70 degree angle, low-dose (mean infusion dose, 1.5 +/- 0.45 microgram/min), 3 micrograms/min, and 5 micrograms/min isoproterenol infusions elicited an abnormal response in 1 (4%), 5 (20%), and 14 (56%) of the subjects, respectively. Using multiple logistic regression analysis, head-up tilt testing at an 80 degree angle (P = .01) or during 3 micrograms/min (P = .02) and 5 micrograms/min isoproterenol infusion rates (P < .001) was the most significant predictor of an abnormal response. CONCLUSIONS: Head-up tilt testing at a 60 or 70 degree angle with or without low-dose isoproterenol infusion provides an adequate specificity. Caution is needed, however, in interpreting the results if the head-up tilt test at 80 degrees is extended beyond 10 minutes or if high doses of isoproterenol are used.

Adult↗
PubMed1995

Termination of atrioventricular nodal reentrant tachycardia by premature stimulation from ablating catheter. A reliable guide to identify site for slow-pathway ablation.

BACKGROUND: Slow-pathway ablation is currently used more frequently to control atrioventricular nodal reentrant tachycardia (AVNRT). However, in patients with the common type of AVNRT, successful ablation of the slow pathway can be difficult and time-consuming. We tested a simple method to predict a site for slow-pathway ablation in patients with AVNRT of the common variety. METHODS AND RESULTS: Twenty patients with symptomatic common AVNRT (13 women and 7 men; mean age, 41 +/- 21 years) were included in the study. Once the AVNRT had a stable cycle length (+/- 10 ms) for at least 20 cycles, single extrastimuli were delivered from the ablating catheter tip beginning with 20 ms less than the tachycardia cycle length and decrementing by 10 ms until tachycardia terminated or loss of capture occurred at the pacing site. The pacing protcol was performed systematically in a stepwise fashion at four adjacent sites starting from the posterior/inferior interatrial septum near the tricuspid annulus and moving progressively more anteriorly. The pacing protocol was then repeated in the same sequence, followed by delivery of radiofrequency current at each site to determine its effect at sites where AVNRT could not be terminated with a pacing protocol. AVNRT could be terminated in the anterograde direction from at least one site in 19 patients. Tachycardia could be terminated at two or more adjacent sites in 5 patients. The longest atrial coupling interval at the site of tachycardia termination was 67 +/- 27 ms (range, 30 to 130 ms) less than the AVNRT cycle length. Resetting of subsequent His bundle depolarization (H2), producing an H-H2 interval prolongation of 26 +/- 24 ms (range, 10 to 80 ms), occurred in 17 patients before termination of the tachycardia. In 18 of the 19 patients, the slow pathway was successfully ablated at the site at which AVNRT was terminated at the longest atrial coupling interval. CONCLUSIONS: Termination of tachycardia in the anterograde direction at the longest atrial coupling interval by extrastimuli delivered from the ablating catheter can be helpful for identification of an optimal site for slow-pathway ablation in patients with the common variety of AVNRT.

Adult↗
PubMed1995

Relevance of asystole during head-up tilt testing.

The prognosis of patients manifesting prolonged asystole during head-up tilt testing is unclear. In 209 consecutive patients with a history of syncope and positive head-up tilt tests, 19 had asystole lasting > 5 seconds (mean duration 15 +/- 10) (group 1a). When compared with patients without asystole (group 1b), group 1a patients were younger (32 +/- 12 vs 47 +/- 21 years, p < 0.005), but clinical manifestations were not any more dramatic (the number of episodes of syncope [7 +/- 5 vs 8 +/- 6 episodes, p = NS] and injury during syncope [2 vs 13 patients, p = NS] were similar). During follow-up (mean 2 +/- 1 year), with the patient taking pharmacologic therapy such as beta blockers, ephedrine, theophylline, or disopyramide, the recurrence rate was 11% and 8% in groups 1a and 1b (p = NS). No patient in the asystole group underwent pacemaker implantation. Additionally, of 75 normal volunteers (group 2) with no history of syncope undergoing tilt tests to define its specificity, 3 had asystole (mean duration 10 seconds). During > 1 year of follow-up, despite no treatment, all 3 are symptom free. Thus, asystole during head-up tilt testing does not predict either a more malignant outcome or a poor response to pharmacologic therapy. Moreover, an asystolic response does not enhance the specificity of the head-up tilt test because it may be present in asymptomatic "normal" volunteers.

Adolescent↗
PubMed1995

Comparison of biphasic and monophasic pulses: does the advantage of biphasic shocks depend on the waveshape?

With present implantable defibrillators, the ability to vary the defibrillation technique has been shown to increase the number of patients suitable for transvenous system. As newer waveforms become available, the need for a flexible device may change. In addition, although it has been shown that the option of biphasic waveform may increase the defibrillation efficacy, this may depend upon the shape of the biphasic waveform used. Thirty patients undergoing transvenous defibrillator implant were included in the study. In 20 patients (group I), defibrillation efficacy of simultaneous monophasic, sequential monophasic, and biphasic waveform with 50% tilt was determined randomly. Similarly, in ten patients (group II) testing of simultaneous monophasic shocks and biphasic waveforms with 65% and 80% tilt was performed in random order. The electrode system used consisted of two transvenous leads and a subcutaneous patch in all 30 patients. In group I, 50% tilt biphasic waveform consistently provided similar or better defibrillation efficacy compared to monophasic waveforms (biphasic 7.5 +/- 5.1 joules vs simultaneous 17 +/- 7.8 joules, P < 0.01; and vs sequential 17 +/- 8.4 joules, P < 0.01). In group II, 65% tilt biphasic pulse required less energy for defibrillation as compared with simultaneous monophasic shocks (9.6 +/- 4.5 joules vs 15.6 +/- 5.1 joules, P = 0.04). No significant difference was observed in terms of defibrillation threshold between 80% tilt biphasic shocks and simultaneous monophasic pulses (11.8 +/- 6 joules vs 15.6 +/- 5.1 joules, P = NS). Biphasic shocks with smaller tilt delivered using a triple lead system more uniformly improved defibrillation threshold over standard monophasic waveforms.

Defibrillators, Implantable↗
PubMed1995

Effects of initial polarity on defibrillation threshold with biphasic pulses.

BACKGROUND: Previous studies have shown that the polarity of epicardial patches significantly affects the defibrillation efficacy of monophasic shocks. However, whether this improvement can be extended to different pulsing methods and lead systems, such as biphasic shocks using endocardial defibrillating electrodes, is unknown. METHODS: Twenty consecutive patients undergoing testing and permanent implant using an Endotak lead system with a biphasic device were included in the study. In each patient the defibrillation threshold was determined delivering biphasic pulses with the distal coil as the cathode and the proximal coil as the anode during the positive phase and with the polarity reversed. The initial electrode polarity tested was chosen randomly. The defibrillation threshold was defined as the lowest pulse amplitude that effectively terminated ventricular fibrillation induced with 60-Hz alternating current. For each biphasic pulse peak voltage, pulse duration, resistance, and stored energy were recorded. RESULTS: Of the 20 patients, 12 (60%) had lower defibrillation threshold when the proximal coil was negative, whereas only 2 patients had a lower defibrillation threshold when the distal coil was negative. In four patients a subcutaneous patch would have been required if only the biphasic pulse with the distal coil as negative had been tested. The mean stored defibrillation threshold energy was lower with the configuration using the proximal coil as cathode (16.3 +/- 8.8 J vs 21.5 +/- 11 J; P < 0.01). CONCLUSION: Change in the initial polarity of biphasic shocks may influence defibrillation efficacy and should, therefore, be assessed in each patient to achieve a more satisfactory safety margin and minimize the use of more invasive lead configurations.

Defibrillators, Implantable↗
PubMed1995

Efficacy of different treatment strategies for neurocardiogenic syncope.

OBJECTIVES: The purpose of this study was to evaluate the efficacy of different therapeutic approaches for patients with a history of syncope and positive head-up tilt testing. BACKGROUND: Head-up tilt testing has gained broad acceptance as a reliable diagnostic method for the assessment of patients with recurrent unexplained syncope. However, once the diagnosis is established, there is no consensus on the most appropriate treatment. In this respect, efficacy of drug therapy in preventing recurrence of symptoms in such patients is not entirely clear, and controversies exist regarding the need to confirm the effects of pharmacological interventions. METHODS: Clinical follow-up was obtained in 303 patients with a history of syncope and positive head-up tilt testing. After the diagnostic head-up tilt, patients were assigned to different therapeutic approaches according to their preference or logistic impediments. Of 303 patients, 44 received empiric therapy, 210 were treated with medications proven effective during repeated head-up tilt testing, and 49 refused or discontinued medical therapy. The three groups were similar with regard to age, sex, and clinical presentation. The mean follow-up was 2.8 +/- 1.8 years. Among the patients treated according to head-up tilt guided therapy, 130 were on beta blockers, 35 on theophylline, 10 on ephedrine, 31 on disopyramide, and 4 on miscellaneous regimens. Empiric treatment consisted of beta blockers in 37 of 44 patients and other drugs in the remaining patients. RESULTS: During the follow-up, recurrence of symptoms was experienced in 12 (6%) of the 210 patients receiving the head-up tilt guided therapy, 16 (36%) of 44 in the empiric therapy group, and 33 (67%) of 49 in the no therapy group. Recurrence of symptoms in patients on empiric or no therapy was significantly more frequent as compared to the head-up tilt guided therapy group (P < 0.01). CONCLUSIONS: In patients with unexplained syncope and positive upright tilt testing, therapeutic strategies identified on the basis of response during head-up tilt have a more positive impact on the recurrence of symptoms during follow-up.

Adolescent↗
PubMed1995

Posteroseptal accessory pathways: an overview of anatomical characteristics, electrocardiographic patterns, electrophysiological features, and ablative therapy.

First, the posteroseptal region of the heart is probably the most complex area among those that harbor AV accessory fibers and a firm grasp of the anatomical characteristics of this region may facilitate achieving a successful AP ablation. Second, there is no sharp demarcation between the posteroseptal area and its surrounding regions including mid-septal, left posterior paraseptal, and right posterior paraseptal locations. Therefore, there are some inevitable overlaps between the electrocardiographic and electrophysiological features of APs located in the posteroseptal region and those areas immediately adjacent to it. Third, in the vast majority of cases, successful ablation can be achieved using a right atrial approach. Therefore, dividing posteroseptal APs into right- or left-sided pathways may only be useful for describing their ECG or electrophysiological characteristics with little or no value in predicting the site of successful ablation. Fourth, it seems advisable to attempt efforts to induce functional bundle branch block during orthodromic tachycardia and assess its effect on the VA interval. Ventriculoatrial interval prolongation due to right bundle branch block strongly favors a right free-wall or anteroseptal AP location. Prolongation of the VA interval by 30 msec or less in response to left bundle branch block is compatible with a posteroseptal location. In this situation, the mapping and ablative efforts should primarily be focused on the right atrial approach, including the terminal coronary sinus. If left bundle branch block causes VA interval lengthening of 30 msec or greater, the AP is most likely in the left free-wall region, including the posterior paraseptal area. Finally, the presence of APs having an intimate relationship with the middle cardiac (posterior interventricular) vein or the coronary sinus pouch, although exceedingly uncommon, should be considered in difficult cases in which radiofrequency applications to the conventional posteroseptal locations are unsuccessful. Such cases may require coronary sinus venography for better visualization and precise mapping of the terminal sinus complex.

Arrhythmias, Cardiac↗
PubMed1995

Catheter ablation in supraventricular tachycardia.

The evolution of catheter ablation for the treatment of supraventricular tachycardias represents a major advance in the management of cardiac arrhythmias. Excellent results in the majority of patients undergoing the procedure, together with a low rate of early complications and a brief hospitalization, make catheter ablation a highly cost-effective permanent cure. At present, however, its place in relation to alternate therapies in the management of supraventricular tachycardias has not been clearly established owing to unresolved risk-benefit issues. Continuing technical advances will likely enable catheter ablation to be successfully applied to a broader range of cardiac arrhythmias.

Anti-Arrhythmia Agents↗
PubMed1994

Feasibility of concomitant implantation of permanent transvenous pacemaker and defibrillator systems.

In 17 patients (14 men and 3 women aged 69 +/- 10 years), a transvenous pacemaker was implanted before (8 patients), following (7 patients), or simultaneously (2 patients) with the insertion of a transvenous defibrillator. Indications included malignant ventricular arrhythmias and symptomatic bradycardia in all patients. All patients had structural heart disease. All pacemakers were non-programmable bipolar, either single chamber (n = 7) or dual chamber (n = 10). Eleven pacemakers were rate responsive. The Transvene system was implanted in 7 patients (Pacer-Cardioverter-Defibrillator in 6 patients and the Cadence defibrillator in 1). The Endotak lead system was implanted in 10 patients (Ventak in 7 patients and the Cadence in 3). The mean defibrillation threshold was 16 +/- 5 J. Repositioning of the pacemaker leads eliminated undersensing of ventricular fibrillation by the defibrillator, which occurred during asynchronous pacing in 2 patients. During a mean follow-up of 11 +/- 6 months, 2 patients died because of pump failure and 7 patients received defibrillator therapy for ventricular arrhythmias. No significant complications were noted. Successful concomitant implantation of transvenous pacemakers and defibrillators was thus accomplished in 17 patients, which suggests that insertion of a second transvenous device can be safely accomplished.

Adult↗
PubMed1994

Circulatory and catecholamine changes during head-up tilt testing in neurocardiogenic (vasovagal) syncope.

Changes in heart rate, arterial pressure, norepinephrine and epinephrine levels were compared in 19 consecutive patients (10 men and 9 women, mean age 46 +/- 16 years) with neurocardiogenic syncope and 11 age- and sex-matched control subjects (5 men and 6 women, mean age 49 +/- 15 years) during head-up tilt testing. Norepinephrine and epinephrine levels were measured at the baseline supine position, in the initial upright position, every 90 seconds during the 70 degrees upright tilt, at the time of termination due to hypotension and syncope (or at 15 minutes in control subjects), and at 40 seconds and 1 minute and 40 seconds in the supine position after terminating the head-up tilt test. Baseline norepinephrine, epinephrine and heart rate were slightly higher in patients. Despite a significant decrease in mean arterial pressure during head-up tilt testing in patients (51 +/- 20 mm Hg; p < 0.001), norepinephrine levels in patients and control subjects at the time of terminating the head-up tilt test were comparable (459 +/- 204 vs 473 +/- 172 pg/ml). A fivefold increase in epinephrine levels (73 +/- 53 to 345 +/- 260 pg/ml; p < 0.01) were seen in patients, whereas control subjects had insignificant change (38 +/- 16 to 65 +/- 44 pg/ml). It is concluded that diminished neuronal sympathetic activity and enhanced adrenomedullary activity is demonstrated during head-up tilt testing in patients with neurocardiogenic syncope.

Adult↗
PubMed1994

Catheter ablation of ventricular tachycardia.

The role and success rate of catheter ablation for monomorphic ventricular tachycardia (VT) depend on the mechanism and origin of the tachycardia (i.e., myocardial versus His-Purkinje system) and whether it occurs in the presence or absence of structural heart diseases. For sustained bundle-branch reentry, a form of VT associated with structural heart disease, radiofrequency catheter ablation of the right bundle-branch can be performed readily and is highly successful in eliminating this arrhythmia. Because of modest success rates of catheter ablation of VT associated with a prior infarction (between 17% and 75%), this treatment modality is usually considered for cases refractory to drug therapy and should be viewed as adjunctive therapy. The target for ablation is a critical area of slow conduction, which is selected based on earliest endocardial activation, mid-diastolic potentials, concealed entrainment, or pace mapping. Radiofrequency catheter ablation may be the treatment of choice in patients with VT and no apparent structural heart disease; this is especially true for young patients who would otherwise require long-life antiarrhythmic therapy. Success rates between 75% and 100% have been reported, especially when the origin is in the right ventricular outflow tract.

Bundle-Branch Block↗